176 related articles for article (PubMed ID: 30798431)
1. Acromegaly can be cured by first-line pasireotide treatment?
Chiloiro S; Giampietro A; Bianchi A; Tartaglione T; Bima C; Vita MG; Spinello M; Pontecorvi A; De Marinis L
Endocrine; 2019 Apr; 64(1):196-199. PubMed ID: 30798431
[No Abstract] [Full Text] [Related]
2. Evolution of (18)FDG pituitary uptake after medical control of acromegaly.
Maiza JC; Revel C
Pituitary; 2014 Jun; 17(3):296-7. PubMed ID: 23982451
[No Abstract] [Full Text] [Related]
3. Potential antitumour activity of pasireotide on pituitary tumours in acromegaly.
Coopmans EC; van der Lely AJ; Schneiders JJ; Neggers SJCMM
Lancet Diabetes Endocrinol; 2019 Jun; 7(6):425-426. PubMed ID: 30956093
[No Abstract] [Full Text] [Related]
4. Pasireotide in acromegaly by aggressive tumors, description of four clinical cases. Towards a personalized medicine.
Biagetti B; Obiols G; Martinez Saez E; Cordero E; Mesa J
Endocrinol Diabetes Nutr (Engl Ed); 2018 Feb; 65(2):130-132. PubMed ID: 29371000
[No Abstract] [Full Text] [Related]
5. Pasireotide and Pegvisomant Combination Treatment in Acromegaly Resistant to Second-Line Therapies: A Longitudinal Study.
Chiloiro S; Bima C; Tartaglione T; Giampietro A; Gessi M; Lauretti L; Anile C; Colosimo C; Rindi G; Pontecorvi A; De Marinis L; Bianchi A
J Clin Endocrinol Metab; 2019 Nov; 104(11):5478-5482. PubMed ID: 31219586
[TBL] [Abstract][Full Text] [Related]
6. [Outcome of somatostatin analogue treatment in acromegaly].
Mondok A; Tóth M; Patócs A; Szücs N; Igaz P; Pusztai P; Czirják S; Beko G; Gláz E; Rácz K; Tulassay Z
Orv Hetil; 2009 Aug; 150(31):1457-62. PubMed ID: 19617182
[TBL] [Abstract][Full Text] [Related]
7. Long-term efficacy and safety of subcutaneous pasireotide in acromegaly: results from an open-ended, multicenter, Phase II extension study.
Petersenn S; Farrall AJ; De Block C; Melmed S; Schopohl J; Caron P; Cuneo R; Kleinberg D; Colao A; Ruffin M; Hermosillo Reséndiz K; Hughes G; Hu K; Barkan A
Pituitary; 2014 Apr; 17(2):132-40. PubMed ID: 23529827
[TBL] [Abstract][Full Text] [Related]
8. Pituitary gangliocytoma-adenoma presenting with acromegaly: response to treatment.
Luna V; Morales F; Luengo LM; Sanz A; Diaz J
Arch Intern Med; 2001 Apr; 161(7):1010-1. PubMed ID: 11295968
[No Abstract] [Full Text] [Related]
9. 111Indium-pentetreotide pituitary scintigraphy and hormonal responses to octreotide in acromegalic patients.
Legovini P; De Menis E; Billeci D; Conti B; Zoli P; Conte N
J Endocrinol Invest; 1997; 20(7):424-8. PubMed ID: 9309542
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of long-acting pasireotide in patients with somatostatin-resistant acromegaly: a multicenter study.
Shimon I; Adnan Z; Gorshtein A; Baraf L; Saba Khazen N; Gershinsky M; Pauker Y; Abid A; Niven MJ; Shechner C; Greenman Y
Endocrine; 2018 Nov; 62(2):448-455. PubMed ID: 30051198
[TBL] [Abstract][Full Text] [Related]
11. Surgical debulking of pituitary macroadenomas causing acromegaly improves control by lanreotide.
Karavitaki N; Turner HE; Adams CB; Cudlip S; Byrne JV; Fazal-Sanderson V; Rowlers S; Trainer PJ; Wass JA
Clin Endocrinol (Oxf); 2008 Jun; 68(6):970-5. PubMed ID: 18031313
[TBL] [Abstract][Full Text] [Related]
12. Extraocular muscle enlargement in acromegaly.
Dal Pozzo G; Boschi MC
J Comput Assist Tomogr; 1982 Aug; 6(4):706-7. PubMed ID: 7119187
[No Abstract] [Full Text] [Related]
13. Serial follow-up of presurgical treatment using pasireotide long-acting release with or without octreotide long-acting release for naïve active acromegaly.
Chang JS; Tseng HM; Chang TC
J Formos Med Assoc; 2016 Jun; 115(6):475-80. PubMed ID: 27117887
[TBL] [Abstract][Full Text] [Related]
14. [Prediction of pharmacological effect of octreotide in acromegaly by means of 111In-pentetreotide scintigraphy and calculation of a pituitary uptake index].
Görges R; Cordes U; Engelbach M; Bartelt KM; Haberern G; Hey O; Beyer J; Bockisch A
Nuklearmedizin; 1997 Jun; 36(4):117-24. PubMed ID: 9289697
[TBL] [Abstract][Full Text] [Related]
15. Impact of preoperative pasireotide therapy on invasive octreotide-resistant acromegaly.
Yamamoto R; Robert Shima K; Igawa H; Kaikoi Y; Sasagawa Y; Hayashi Y; Inoshita N; Fukuoka H; Takahashi Y; Takamura T
Endocr J; 2018 Oct; 65(10):1061-1067. PubMed ID: 30078825
[TBL] [Abstract][Full Text] [Related]
16. Elbow arthrosis as an initial presentation of acromegaly.
Tsai E; Freiberg AA; Louis DS
Orthopedics; 1998 Aug; 21(8):901-2. PubMed ID: 9731673
[No Abstract] [Full Text] [Related]
17. Reduction in sella turcica volume. An effect of long-term treatment with the somatostatin analogue, SMS 201-995, in acromegalic patients.
Lund E; Jørgensen J; Christensen SE; Weeke J; Orskov H; Harris AG
Neuroradiology; 1991; 33(2):162-4. PubMed ID: 2046904
[TBL] [Abstract][Full Text] [Related]
18. Intensity of pituitary adenoma on T2-weighted magnetic resonance imaging predicts the response to octreotide treatment in newly diagnosed acromegaly.
Heck A; Ringstad G; Fougner SL; Casar-Borota O; Nome T; Ramm-Pettersen J; Bollerslev J
Clin Endocrinol (Oxf); 2012 Jul; 77(1):72-8. PubMed ID: 22066905
[TBL] [Abstract][Full Text] [Related]
19. Long-term treatment of acromegaly with the somatostatin analogue SR-lanreotide.
Suliman M; Jenkins R; Ross R; Powell T; Battersby R; Cullen DR
J Endocrinol Invest; 1999 Jun; 22(6):409-18. PubMed ID: 10435849
[TBL] [Abstract][Full Text] [Related]
20. Co-existing pituitary adenoma and intrasellar arachnoid invagination.
Sutton TJ; Vezina JL
Am J Roentgenol Radium Ther Nucl Med; 1974 Nov; 122(3):508-10. PubMed ID: 4432974
[No Abstract] [Full Text] [Related]
[Next] [New Search]
